GlassScriptPhysician profile
Hebroon Obaid
NPI 1447660204
$8,483.81
in general payments reported to CMS, 2019-2025
7 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.13 · 2022: $3,532 · 2023: $309 · 2024: $4,098 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,614 · Food and Beverage: $2,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,613.89 |
| Food and Beverage | $2,268.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $4,214.64 | 2021-2025 | Mitris Resilia Mitral Valve, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Atricure, INC. | $3,582.45 | 2022-2024 | |
| Artivion, INC. | $546.89 | 2024 | On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder |
| Medtronic, INC. | $81.27 | 2021-2025 | Cardioblate |
| Ethicon US, LLC | $22.78 | 2024 | Stratafix, Dermabond Prineo |
| Shockwave Medical, INC | $19.32 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Getinge USA Sales, LLC | $16.46 | 2023 | Vasoview Hemopro 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hebroon Obaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.